AGIO up +7.12% percent Today $AGIO High is at 77.9
Post# of 83
Posted On: 11/10/2014 12:11:53 PM
AGIO up +7.12% percent Today $AGIO High is at 77.93 and the Low 73.24 with current volume of 454,025.
Recent News posted below.
Agios Pharmaceuticals Inc AGIO other info.
http://investorshangout.com/Agios-Pharmaceuti...GIO-90049/
AGIO Agios Pharmaceuticals Inc Recent Headline News
Agios Pharmaceuticals posts 3Q profit
Automated Insights - Fri Nov 07, 6:09AM CST
CAMBRIDGE, Mass. (AP) _ Agios Pharmaceuticals Inc. (AGIO) on Friday reported earnings of $3.7 million, or 10 cents per share, in its third quarter.
AGIO: 76.81 (+4.75)
Agios Pharmaceuticals Reports Third Quarter 2014 Financial Results
GlobeNewswire - Fri Nov 07, 6:00AM CST
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today reported business highlights and financial results for the third quarter ended September 30, 2014.
AGIO: 76.81 (+4.75)
Will Agios (AGIO) Disappoint in the Q3 Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 4:10PM CST
Agios (AGIO), which is scheduled to report third-quarter results on Nov 7, had delivered a negative earnings surprise of 14.89% in the last quarter.
MNK: 92.66 (+1.60), RNA: 11.99 (-0.15), AGIO: 76.81 (+4.75), CELG: 107.81 (+1.36)
Agios Pharmaceuticals to Present Clinical and Preclinical Data at the 2014 American Society of Hematology Annual Meeting
GlobeNewswire - Thu Nov 06, 8:46AM CST
New Data from Ongoing Phase 1 AG-221 Trial Accepted for Oral Presentation
AGIO: 76.81 (+4.75)
Critical Alerts For LinkedIn, Imperva Inc, Norfolk Southern, Halliburton and Agios Pharmaceuticals Released By InvestorsObserver
PR Newswire - Mon Nov 03, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for LNKD, IMPV, NSC, HAL and AGIO.
NSC: 116.17 (+3.31), LNKD: 227.67 (+4.63), HAL: 53.61 (-0.25), AGIO: 76.81 (+4.75), IMPV: 42.64 (+0.11)
Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 108.11 (+1.66), CLVS: 58.39 (+0.08), ARWR: 6.35 (+0.29), ACHN: 12.37 (+2.26), MRK: 58.67 (-0.67), RTRX: 10.18 (-0.20), RGLS: 22.85 (+0.77), EPZM: 23.42 (-0.33), AGIO: 76.81 (+4.75), RMTI: 10.34 (-0.21), ARNA: 4.32 (+0.06), KERX: 16.47 (-0.26)
'Mad Money' Lightning Round: I'm Sticking With Isis Pharmaceuticals
at The Street - Wed Oct 29, 5:00AM CDT
Cramer says Halliburton is a buy, buy, buy and GNC needs to merge with Vitamin Shoppe.
VSI: 47.44 (+0.80), RICE: 28.30 (-0.88), GS: 191.44 (+0.73), FEYE: 31.98 (+1.36), ISIS: 46.19 (+1.60), CYBR: 34.00 (+1.29), GNC: 42.87 (-0.19), HAL: 53.61 (-0.25), EOG: 99.15 (-0.40), AGIO: 76.81 (+4.75), FTNT: 27.13 (+0.03)
Jim Cramer's 'Mad Money' Recap: Winners in the Expectations Game
at The Street - Tue Oct 28, 7:26PM CDT
It's expectations, not the earnings, that determine the direction of a company's stock price, and several companies proved that today, Cramer says.
KSS: 57.15 (-0.07), FEYE: 31.98 (+1.36), CYBR: 34.00 (+1.29), FB: 74.89 (-0.71), GNC: 42.87 (-0.19), HAL: 53.61 (-0.25), AGCO: 45.03 (-0.52), BWLD: 159.04 (+1.53), MAS: 23.32 (-0.03), YHOO: 49.20 (+0.65), WHR: 174.91 (-0.90), VSI: 47.44 (+0.80), SAVE: 78.35 (+1.04), RICE: 28.30 (-0.88), GS: 191.44 (+0.73), PH: 128.47 (-0.03), ISIS: 46.19 (+1.60), CMI: 146.29 (+0.25), EOG: 99.15 (-0.40), AGIO: 76.81 (+4.75), TWTR: 39.98 (-0.33), FTNT: 27.13 (+0.03), BABA: 116.28 (+1.72)
Can Celgene Corporation Stock Motor to $150 Following Earnings?
Sean Williams, The Motley Fool - Motley Fool - Tue Oct 28, 7:03AM CDT
Just as the proverbial American worker stamps their time card on a daily basis and does their job, biotech giant Celgene continues to deliver for shareholders without fail. Last Thursday, Celgene dazzled investors yet again by reporting better...
OMED: 20.10 (-0.09), AGIO: 76.81 (+4.75), CELG: 107.81 (+1.36)
Forget MannKind Corporation: 3 Better Stocks
Motley Fool Staff - Motley Fool - Mon Oct 27, 8:13AM CDT
Source: MannKind. A doubling of Americans diagnosed with diabetes over the coming decade may support demand for MannKind 's inhalable insulin Afrezza, but that doesn't necessarily mean that MannKind is biotech's best idea. We asked three of...
DXCM: 52.63 (+1.70), NVAX: 5.09 (+0.14), AGIO: 76.81 (+4.75), SNY: 46.33 (+0.64), MNKD: 5.81 (+0.03), CELG: 107.81 (+1.36)
Agios Pharmaceuticals to Webcast Conference Call of Third Quarter 2014 Financial Results on November 7, 2014
GlobeNewswire - Mon Oct 27, 7:41AM CDT
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that it will host a conference call and live webcast on Friday, November 7, 2014, at 8:00 a.m. EST to report its third quarter 2014 financial results and discuss recent business activities.
AGIO: 76.81 (+4.75)
3 Momentum Stocks to Watch in Biotechnology for Continued Upside
at The Street - Thu Oct 23, 2:39PM CDT
Wednesday was a strong session for a number of stocks, and here are three, in particular, to watch for more upside.
BABY: 34.06 (+0.91), RGLS: 22.89 (+0.81), AGIO: 76.81 (+4.75)
Agios Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of AG-221 in Patients with Advanced Solid Tumors with an IDH2 Mutation
GlobeNewswire - Tue Oct 21, 7:39AM CDT
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced the initiation of a Phase 1/2 multicenter study of AG-221 in patients with advanced solid tumors, including gliomas, as well as angioimmunoblastic T-cell lymphoma (AITL) that carry an isocitrate dehydrogenase-2 (IDH2) mutation. The study will enroll patients who have recurred or progressed following standard therapy or have not responded to prior standard therapy. This is the second trial to be initiated in patients with cancer as part of AG-221's clinical development program, which includes the ongoing Phase 1 trial with four expansion cohorts in patients with hematologic malignancies.
AGIO: 76.81 (+4.75)
Agios (AGIO) Rises on Expansion of Phase I Study on AG-221 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 3:10PM CDT
Agios Pharmaceuticals (AGIO) initiated four expansion cohorts in its ongoing phase I study on AG-221.
MDVN: 110.04 (-2.73), EBS: 23.96 (+0.01), AGIO: 76.81 (+4.75), CELG: 107.81 (+1.36)
Agios Pharmaceuticals Announces Initiation of Four Expansion Cohorts in Phase 1 Study of AG-221
GlobeNewswire - Wed Oct 15, 6:30AM CDT
Once-Daily Oral Dose Selected From Ongoing Phase 1 Study of AG-221 in Hematologic Malignancies
AGIO: 76.81 (+4.75)
Insider Trading Alert - AGIO, ACN And CTAS Traded By Insiders
at The Street - Mon Oct 06, 9:06AM CDT
Stocks with insider trader activity include AGIO, ACN and CTAS
CTAS: 71.20 (+0.20), AGIO: 76.81 (+4.75), ACN: 84.20 (+0.72)
Agios Pharmaceuticals to Webcast R&D Day on October 15, 2014
GlobeNewswire - Mon Oct 06, 8:33AM CDT
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that the company will webcast presentations at its Research and Development (R&D) Day on Wednesday, October 15, 2014, from 9:00 a.m. to approximately 12:00 p.m. EDT in New York City.
AGIO: 76.81 (+4.75)
Earnings Release Schedules, Data Presentation, Regulatory Approvals, and Strategic Collaboration - Research Reports on Covidien, Biogen, Amgen, Agios and Baxter
PR Newswire - Wed Oct 01, 7:55AM CDT
Today, Analysts Review released its research reports regarding Covidien plc (NYSE: COV), Biogen Idec Inc. (NASDAQ: BIIB), Amgen Inc. (NASDAQ: AMGN), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and Baxter International Inc. (NYSE: BAX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6893-100free.
BIIB: 324.88 (+4.13), BAX: 70.55 (-0.06), COV: 92.61 (+0.53), AMGN: 162.51 (+2.26), AGIO: 76.81 (+4.75)
Agios to Present Data on AG-120 in November, Shares Rises - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 4:30PM CDT
Shares of Agios Pharmaceuticals (AGIO) jumped 19.3% on the announcement that it will present data on AG-120 earlier than expected.
MDVN: 110.04 (-2.73), GILD: 108.11 (+1.66), AGIO: 76.81 (+4.75), CELG: 107.81 (+1.36)
Critical Alerts For Invensense, Agios Pharmaceuticals, SPDR Gold Trust, Nu Skin Enterprises and Nike Released By InvestorsObserver
PR Newswire - Mon Sep 29, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for INVN, AGIO, GLD, NUS and NKE.
NKE: 94.71 (+0.93), NUS: 42.69 (+2.19), GLD: 111.23 (-1.74), INVN: 15.19 (-0.01), AGIO: 76.81 (+4.75)
Recent News posted below.
Agios Pharmaceuticals Inc AGIO other info.
http://investorshangout.com/Agios-Pharmaceuti...GIO-90049/
AGIO Agios Pharmaceuticals Inc Recent Headline News
Agios Pharmaceuticals posts 3Q profit
Automated Insights - Fri Nov 07, 6:09AM CST
CAMBRIDGE, Mass. (AP) _ Agios Pharmaceuticals Inc. (AGIO) on Friday reported earnings of $3.7 million, or 10 cents per share, in its third quarter.
AGIO: 76.81 (+4.75)
Agios Pharmaceuticals Reports Third Quarter 2014 Financial Results
GlobeNewswire - Fri Nov 07, 6:00AM CST
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today reported business highlights and financial results for the third quarter ended September 30, 2014.
AGIO: 76.81 (+4.75)
Will Agios (AGIO) Disappoint in the Q3 Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 4:10PM CST
Agios (AGIO), which is scheduled to report third-quarter results on Nov 7, had delivered a negative earnings surprise of 14.89% in the last quarter.
MNK: 92.66 (+1.60), RNA: 11.99 (-0.15), AGIO: 76.81 (+4.75), CELG: 107.81 (+1.36)
Agios Pharmaceuticals to Present Clinical and Preclinical Data at the 2014 American Society of Hematology Annual Meeting
GlobeNewswire - Thu Nov 06, 8:46AM CST
New Data from Ongoing Phase 1 AG-221 Trial Accepted for Oral Presentation
AGIO: 76.81 (+4.75)
Critical Alerts For LinkedIn, Imperva Inc, Norfolk Southern, Halliburton and Agios Pharmaceuticals Released By InvestorsObserver
PR Newswire - Mon Nov 03, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for LNKD, IMPV, NSC, HAL and AGIO.
NSC: 116.17 (+3.31), LNKD: 227.67 (+4.63), HAL: 53.61 (-0.25), AGIO: 76.81 (+4.75), IMPV: 42.64 (+0.11)
Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 108.11 (+1.66), CLVS: 58.39 (+0.08), ARWR: 6.35 (+0.29), ACHN: 12.37 (+2.26), MRK: 58.67 (-0.67), RTRX: 10.18 (-0.20), RGLS: 22.85 (+0.77), EPZM: 23.42 (-0.33), AGIO: 76.81 (+4.75), RMTI: 10.34 (-0.21), ARNA: 4.32 (+0.06), KERX: 16.47 (-0.26)
'Mad Money' Lightning Round: I'm Sticking With Isis Pharmaceuticals
at The Street - Wed Oct 29, 5:00AM CDT
Cramer says Halliburton is a buy, buy, buy and GNC needs to merge with Vitamin Shoppe.
VSI: 47.44 (+0.80), RICE: 28.30 (-0.88), GS: 191.44 (+0.73), FEYE: 31.98 (+1.36), ISIS: 46.19 (+1.60), CYBR: 34.00 (+1.29), GNC: 42.87 (-0.19), HAL: 53.61 (-0.25), EOG: 99.15 (-0.40), AGIO: 76.81 (+4.75), FTNT: 27.13 (+0.03)
Jim Cramer's 'Mad Money' Recap: Winners in the Expectations Game
at The Street - Tue Oct 28, 7:26PM CDT
It's expectations, not the earnings, that determine the direction of a company's stock price, and several companies proved that today, Cramer says.
KSS: 57.15 (-0.07), FEYE: 31.98 (+1.36), CYBR: 34.00 (+1.29), FB: 74.89 (-0.71), GNC: 42.87 (-0.19), HAL: 53.61 (-0.25), AGCO: 45.03 (-0.52), BWLD: 159.04 (+1.53), MAS: 23.32 (-0.03), YHOO: 49.20 (+0.65), WHR: 174.91 (-0.90), VSI: 47.44 (+0.80), SAVE: 78.35 (+1.04), RICE: 28.30 (-0.88), GS: 191.44 (+0.73), PH: 128.47 (-0.03), ISIS: 46.19 (+1.60), CMI: 146.29 (+0.25), EOG: 99.15 (-0.40), AGIO: 76.81 (+4.75), TWTR: 39.98 (-0.33), FTNT: 27.13 (+0.03), BABA: 116.28 (+1.72)
Can Celgene Corporation Stock Motor to $150 Following Earnings?
Sean Williams, The Motley Fool - Motley Fool - Tue Oct 28, 7:03AM CDT
Just as the proverbial American worker stamps their time card on a daily basis and does their job, biotech giant Celgene continues to deliver for shareholders without fail. Last Thursday, Celgene dazzled investors yet again by reporting better...
OMED: 20.10 (-0.09), AGIO: 76.81 (+4.75), CELG: 107.81 (+1.36)
Forget MannKind Corporation: 3 Better Stocks
Motley Fool Staff - Motley Fool - Mon Oct 27, 8:13AM CDT
Source: MannKind. A doubling of Americans diagnosed with diabetes over the coming decade may support demand for MannKind 's inhalable insulin Afrezza, but that doesn't necessarily mean that MannKind is biotech's best idea. We asked three of...
DXCM: 52.63 (+1.70), NVAX: 5.09 (+0.14), AGIO: 76.81 (+4.75), SNY: 46.33 (+0.64), MNKD: 5.81 (+0.03), CELG: 107.81 (+1.36)
Agios Pharmaceuticals to Webcast Conference Call of Third Quarter 2014 Financial Results on November 7, 2014
GlobeNewswire - Mon Oct 27, 7:41AM CDT
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that it will host a conference call and live webcast on Friday, November 7, 2014, at 8:00 a.m. EST to report its third quarter 2014 financial results and discuss recent business activities.
AGIO: 76.81 (+4.75)
3 Momentum Stocks to Watch in Biotechnology for Continued Upside
at The Street - Thu Oct 23, 2:39PM CDT
Wednesday was a strong session for a number of stocks, and here are three, in particular, to watch for more upside.
BABY: 34.06 (+0.91), RGLS: 22.89 (+0.81), AGIO: 76.81 (+4.75)
Agios Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of AG-221 in Patients with Advanced Solid Tumors with an IDH2 Mutation
GlobeNewswire - Tue Oct 21, 7:39AM CDT
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced the initiation of a Phase 1/2 multicenter study of AG-221 in patients with advanced solid tumors, including gliomas, as well as angioimmunoblastic T-cell lymphoma (AITL) that carry an isocitrate dehydrogenase-2 (IDH2) mutation. The study will enroll patients who have recurred or progressed following standard therapy or have not responded to prior standard therapy. This is the second trial to be initiated in patients with cancer as part of AG-221's clinical development program, which includes the ongoing Phase 1 trial with four expansion cohorts in patients with hematologic malignancies.
AGIO: 76.81 (+4.75)
Agios (AGIO) Rises on Expansion of Phase I Study on AG-221 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 3:10PM CDT
Agios Pharmaceuticals (AGIO) initiated four expansion cohorts in its ongoing phase I study on AG-221.
MDVN: 110.04 (-2.73), EBS: 23.96 (+0.01), AGIO: 76.81 (+4.75), CELG: 107.81 (+1.36)
Agios Pharmaceuticals Announces Initiation of Four Expansion Cohorts in Phase 1 Study of AG-221
GlobeNewswire - Wed Oct 15, 6:30AM CDT
Once-Daily Oral Dose Selected From Ongoing Phase 1 Study of AG-221 in Hematologic Malignancies
AGIO: 76.81 (+4.75)
Insider Trading Alert - AGIO, ACN And CTAS Traded By Insiders
at The Street - Mon Oct 06, 9:06AM CDT
Stocks with insider trader activity include AGIO, ACN and CTAS
CTAS: 71.20 (+0.20), AGIO: 76.81 (+4.75), ACN: 84.20 (+0.72)
Agios Pharmaceuticals to Webcast R&D Day on October 15, 2014
GlobeNewswire - Mon Oct 06, 8:33AM CDT
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that the company will webcast presentations at its Research and Development (R&D) Day on Wednesday, October 15, 2014, from 9:00 a.m. to approximately 12:00 p.m. EDT in New York City.
AGIO: 76.81 (+4.75)
Earnings Release Schedules, Data Presentation, Regulatory Approvals, and Strategic Collaboration - Research Reports on Covidien, Biogen, Amgen, Agios and Baxter
PR Newswire - Wed Oct 01, 7:55AM CDT
Today, Analysts Review released its research reports regarding Covidien plc (NYSE: COV), Biogen Idec Inc. (NASDAQ: BIIB), Amgen Inc. (NASDAQ: AMGN), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and Baxter International Inc. (NYSE: BAX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6893-100free.
BIIB: 324.88 (+4.13), BAX: 70.55 (-0.06), COV: 92.61 (+0.53), AMGN: 162.51 (+2.26), AGIO: 76.81 (+4.75)
Agios to Present Data on AG-120 in November, Shares Rises - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 4:30PM CDT
Shares of Agios Pharmaceuticals (AGIO) jumped 19.3% on the announcement that it will present data on AG-120 earlier than expected.
MDVN: 110.04 (-2.73), GILD: 108.11 (+1.66), AGIO: 76.81 (+4.75), CELG: 107.81 (+1.36)
Critical Alerts For Invensense, Agios Pharmaceuticals, SPDR Gold Trust, Nu Skin Enterprises and Nike Released By InvestorsObserver
PR Newswire - Mon Sep 29, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for INVN, AGIO, GLD, NUS and NKE.
NKE: 94.71 (+0.93), NUS: 42.69 (+2.19), GLD: 111.23 (-1.74), INVN: 15.19 (-0.01), AGIO: 76.81 (+4.75)
(0)
(0)Agios Pharmaceuticals Inc. (AGIO) Stock Research Links
Scroll down for more posts ▼